 Zhiying You
Concepts (265)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 16 | 2024 | 567 | 1.640 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 10 | 2024 | 254 | 1.350 |
Why?
| | Acute Kidney Injury | 7 | 2023 | 789 | 0.710 |
Why?
| | Endothelium, Vascular | 6 | 2021 | 902 | 0.620 |
Why?
| | Glomerular Filtration Rate | 12 | 2024 | 711 | 0.610 |
Why?
| | Kidney Failure, Chronic | 6 | 2023 | 546 | 0.580 |
Why?
| | Kidney | 10 | 2022 | 1383 | 0.510 |
Why?
| | Vascular Stiffness | 4 | 2021 | 467 | 0.490 |
Why?
| | Uric Acid | 3 | 2021 | 161 | 0.450 |
Why?
| | Kidney Diseases | 3 | 2022 | 382 | 0.380 |
Why?
| | Cognition | 5 | 2024 | 1124 | 0.380 |
Why?
| | Hypertension | 5 | 2021 | 1242 | 0.370 |
Why?
| | Blood Pressure | 5 | 2021 | 1736 | 0.360 |
Why?
| | Complement System Proteins | 4 | 2022 | 319 | 0.350 |
Why?
| | Blood Vessels | 2 | 2024 | 187 | 0.340 |
Why?
| | Fibroblast Growth Factors | 3 | 2020 | 169 | 0.330 |
Why?
| | Complement Factor B | 2 | 2023 | 109 | 0.330 |
Why?
| | Cardiovascular Diseases | 4 | 2023 | 2008 | 0.330 |
Why?
| | Brachial Artery | 3 | 2020 | 192 | 0.310 |
Why?
| | Metformin | 2 | 2024 | 316 | 0.310 |
Why?
| | Chronic Kidney Disease-Mineral and Bone Disorder | 2 | 2018 | 13 | 0.290 |
Why?
| | Creatinine | 2 | 2020 | 490 | 0.280 |
Why?
| | Sodium | 2 | 2019 | 205 | 0.280 |
Why?
| | Biomarkers | 10 | 2024 | 3969 | 0.270 |
Why?
| | Vasodilation | 3 | 2020 | 476 | 0.270 |
Why?
| | Double-Blind Method | 9 | 2023 | 1875 | 0.270 |
Why?
| | Prospective Studies | 14 | 2023 | 7145 | 0.260 |
Why?
| | Endothelial Cells | 3 | 2021 | 749 | 0.260 |
Why?
| | Critical Illness | 3 | 2023 | 759 | 0.260 |
Why?
| | Oxidative Stress | 2 | 2024 | 1264 | 0.250 |
Why?
| | Phosphates | 2 | 2024 | 181 | 0.250 |
Why?
| | Cognitive Dysfunction | 3 | 2024 | 347 | 0.240 |
Why?
| | Kidney Transplantation | 4 | 2019 | 670 | 0.240 |
Why?
| | Middle Aged | 26 | 2024 | 31165 | 0.240 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 2 | 2024 | 42 | 0.230 |
Why?
| | Lanthanum | 1 | 2024 | 13 | 0.220 |
Why?
| | Renal Dialysis | 2 | 2019 | 423 | 0.220 |
Why?
| | Bicarbonates | 2 | 2023 | 42 | 0.220 |
Why?
| | Male | 34 | 2024 | 63691 | 0.220 |
Why?
| | Humans | 49 | 2024 | 129687 | 0.220 |
Why?
| | Aged | 21 | 2022 | 22101 | 0.210 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2024 | 122 | 0.210 |
Why?
| | Kidney Tubules | 1 | 2024 | 114 | 0.210 |
Why?
| | Pregnancy Complications | 2 | 2018 | 493 | 0.200 |
Why?
| | Caloric Restriction | 1 | 2024 | 111 | 0.200 |
Why?
| | Female | 33 | 2024 | 68751 | 0.200 |
Why?
| | Sodium Bicarbonate | 2 | 2023 | 37 | 0.200 |
Why?
| | Ferric Compounds | 1 | 2022 | 46 | 0.190 |
Why?
| | Sucrose | 1 | 2022 | 103 | 0.190 |
Why?
| | Cardiovascular System | 1 | 2023 | 136 | 0.190 |
Why?
| | Complement Factor H | 1 | 2022 | 73 | 0.190 |
Why?
| | Complement Pathway, Classical | 1 | 2021 | 19 | 0.190 |
Why?
| | Nephrosis, Lipoid | 1 | 2021 | 10 | 0.190 |
Why?
| | Curcumin | 1 | 2021 | 29 | 0.180 |
Why?
| | Breathing Exercises | 1 | 2021 | 20 | 0.180 |
Why?
| | Nephrotic Syndrome | 1 | 2021 | 28 | 0.180 |
Why?
| | Inhalation | 1 | 2021 | 28 | 0.180 |
Why?
| | Respiratory Muscles | 1 | 2021 | 32 | 0.180 |
Why?
| | Carcinoma, Basal Cell | 1 | 2022 | 74 | 0.180 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2021 | 43 | 0.180 |
Why?
| | Cardiolipins | 1 | 2021 | 83 | 0.180 |
Why?
| | Kidney Glomerulus | 1 | 2021 | 109 | 0.180 |
Why?
| | Disease Progression | 7 | 2023 | 2628 | 0.180 |
Why?
| | Peritoneal Dialysis | 1 | 2022 | 95 | 0.180 |
Why?
| | Adult | 20 | 2024 | 35607 | 0.170 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2021 | 102 | 0.170 |
Why?
| | Allopurinol | 2 | 2018 | 62 | 0.170 |
Why?
| | Immunoglobulin M | 1 | 2021 | 276 | 0.170 |
Why?
| | Bone Diseases | 1 | 2020 | 57 | 0.170 |
Why?
| | Lipocalins | 1 | 2019 | 37 | 0.160 |
Why?
| | Antigen-Antibody Complex | 1 | 2019 | 86 | 0.160 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 430 | 0.160 |
Why?
| | Complement C3d | 1 | 2019 | 65 | 0.160 |
Why?
| | Epitopes | 1 | 2021 | 474 | 0.160 |
Why?
| | Vascular Diseases | 1 | 2021 | 240 | 0.150 |
Why?
| | Vascular System Injuries | 1 | 2019 | 73 | 0.150 |
Why?
| | Spironolactone | 1 | 2019 | 30 | 0.150 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 46 | 0.150 |
Why?
| | Renal Replacement Therapy | 1 | 2019 | 87 | 0.150 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2018 | 52 | 0.150 |
Why?
| | Accidental Falls | 1 | 2020 | 169 | 0.150 |
Why?
| | Complement Factor D | 1 | 2018 | 30 | 0.150 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2019 | 541 | 0.150 |
Why?
| | Gene Amplification | 1 | 2018 | 103 | 0.150 |
Why?
| | Fructose | 1 | 2018 | 108 | 0.150 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2018 | 90 | 0.150 |
Why?
| | Regional Blood Flow | 1 | 2020 | 463 | 0.140 |
Why?
| | Potassium, Dietary | 1 | 2018 | 11 | 0.140 |
Why?
| | Infant Mortality | 1 | 2018 | 106 | 0.140 |
Why?
| | Infant, Low Birth Weight | 1 | 2018 | 135 | 0.140 |
Why?
| | Frailty | 1 | 2020 | 152 | 0.140 |
Why?
| | Propensity Score | 1 | 2019 | 265 | 0.140 |
Why?
| | Hyponatremia | 1 | 2018 | 39 | 0.140 |
Why?
| | Sodium, Dietary | 1 | 2018 | 37 | 0.140 |
Why?
| | Antibodies | 1 | 2019 | 399 | 0.140 |
Why?
| | Acidosis | 1 | 2018 | 89 | 0.140 |
Why?
| | Complement Activation | 4 | 2022 | 385 | 0.140 |
Why?
| | Cell-Derived Microparticles | 1 | 2018 | 68 | 0.140 |
Why?
| | Complement Pathway, Alternative | 1 | 2018 | 120 | 0.140 |
Why?
| | Calcitriol | 1 | 2017 | 54 | 0.140 |
Why?
| | Death | 1 | 2018 | 117 | 0.140 |
Why?
| | Cholecalciferol | 1 | 2017 | 56 | 0.140 |
Why?
| | Thrombocytopenia | 1 | 2019 | 189 | 0.140 |
Why?
| | Vascular Calcification | 1 | 2018 | 107 | 0.130 |
Why?
| | Contrast Media | 1 | 2019 | 393 | 0.130 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2019 | 247 | 0.130 |
Why?
| | Hyperuricemia | 1 | 2016 | 44 | 0.130 |
Why?
| | Living Donors | 1 | 2018 | 286 | 0.130 |
Why?
| | Pre-Eclampsia | 1 | 2018 | 187 | 0.130 |
Why?
| | Nitric Oxide | 1 | 2021 | 896 | 0.130 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2018 | 221 | 0.120 |
Why?
| | Peripheral Arterial Disease | 1 | 2021 | 458 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2022 | 829 | 0.110 |
Why?
| | Glioma | 1 | 2018 | 351 | 0.110 |
Why?
| | Recombinant Fusion Proteins | 1 | 2017 | 650 | 0.110 |
Why?
| | Myocardial Infarction | 1 | 2022 | 1021 | 0.110 |
Why?
| | Interleukin-1 | 1 | 2017 | 956 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2017 | 532 | 0.100 |
Why?
| | Risk Factors | 7 | 2022 | 9787 | 0.100 |
Why?
| | Longitudinal Studies | 5 | 2020 | 2724 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 827 | 0.100 |
Why?
| | Lipocalin-2 | 2 | 2024 | 75 | 0.090 |
Why?
| | Case-Control Studies | 4 | 2021 | 3381 | 0.090 |
Why?
| | Time Factors | 5 | 2021 | 6545 | 0.090 |
Why?
| | Healthcare Disparities | 1 | 2017 | 580 | 0.090 |
Why?
| | Follow-Up Studies | 5 | 2019 | 4892 | 0.090 |
Why?
| | Tooth Loss | 1 | 2011 | 26 | 0.090 |
Why?
| | Pulse Wave Analysis | 2 | 2023 | 248 | 0.090 |
Why?
| | Health Services Accessibility | 1 | 2017 | 903 | 0.090 |
Why?
| | Pilot Projects | 3 | 2022 | 1594 | 0.090 |
Why?
| | Severity of Illness Index | 4 | 2020 | 2739 | 0.080 |
Why?
| | Vitamin D | 3 | 2018 | 380 | 0.080 |
Why?
| | Liver | 1 | 2018 | 1839 | 0.080 |
Why?
| | Risk Assessment | 4 | 2021 | 3260 | 0.080 |
Why?
| | Young Adult | 6 | 2023 | 12457 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2021 | 1368 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2018 | 1149 | 0.080 |
Why?
| | Cross-Sectional Studies | 5 | 2020 | 5083 | 0.080 |
Why?
| | United States | 7 | 2024 | 13906 | 0.070 |
Why?
| | Nutritional Status | 2 | 2022 | 328 | 0.070 |
Why?
| | Prognosis | 3 | 2021 | 3772 | 0.070 |
Why?
| | Geography | 1 | 2008 | 188 | 0.070 |
Why?
| | Parathyroid Hormone | 2 | 2018 | 106 | 0.070 |
Why?
| | Mice | 5 | 2022 | 16982 | 0.070 |
Why?
| | Independent Living | 2 | 2018 | 97 | 0.070 |
Why?
| | Self Report | 1 | 2011 | 800 | 0.070 |
Why?
| | Neuropsychological Tests | 2 | 2024 | 1016 | 0.070 |
Why?
| | Coronary Disease | 1 | 2008 | 385 | 0.060 |
Why?
| | Brain | 1 | 2018 | 2677 | 0.060 |
Why?
| | Inflammation Mediators | 2 | 2019 | 505 | 0.060 |
Why?
| | Pregnancy Outcome | 2 | 2018 | 392 | 0.060 |
Why?
| | Health Status Disparities | 1 | 2008 | 256 | 0.060 |
Why?
| | Intensive Care Units | 2 | 2021 | 737 | 0.060 |
Why?
| | Child | 5 | 2023 | 20882 | 0.060 |
Why?
| | Aspirin | 1 | 2008 | 380 | 0.060 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2024 | 19 | 0.060 |
Why?
| | Obesity | 1 | 2017 | 2885 | 0.060 |
Why?
| | Animals | 6 | 2022 | 35404 | 0.060 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2008 | 443 | 0.060 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2024 | 68 | 0.050 |
Why?
| | Chemokine CCL2 | 1 | 2024 | 117 | 0.050 |
Why?
| | Pravastatin | 1 | 2023 | 40 | 0.050 |
Why?
| | Stroke | 2 | 2011 | 1072 | 0.050 |
Why?
| | Incidence | 2 | 2021 | 2644 | 0.050 |
Why?
| | Plant Proteins | 1 | 2023 | 89 | 0.050 |
Why?
| | Sex Factors | 2 | 2020 | 1973 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2021 | 4102 | 0.050 |
Why?
| | Aged, 80 and over | 4 | 2018 | 7064 | 0.050 |
Why?
| | Patched-1 Receptor | 1 | 2022 | 16 | 0.050 |
Why?
| | Hyperphosphatemia | 1 | 2022 | 15 | 0.050 |
Why?
| | Hypoalbuminemia | 1 | 2022 | 30 | 0.050 |
Why?
| | Phosphorus | 1 | 2022 | 92 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2023 | 260 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2021 | 10221 | 0.050 |
Why?
| | Serum Albumin | 1 | 2022 | 149 | 0.050 |
Why?
| | Cohort Studies | 3 | 2018 | 5434 | 0.050 |
Why?
| | Gonadal Steroid Hormones | 1 | 2022 | 132 | 0.050 |
Why?
| | Antibody Specificity | 1 | 2021 | 185 | 0.050 |
Why?
| | Drug Combinations | 1 | 2022 | 331 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2022 | 326 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 188 | 0.040 |
Why?
| | Prevalence | 2 | 2018 | 2563 | 0.040 |
Why?
| | Minerals | 1 | 2020 | 39 | 0.040 |
Why?
| | Mice, Inbred MRL lpr | 1 | 2019 | 38 | 0.040 |
Why?
| | Lymphocytes | 1 | 2022 | 377 | 0.040 |
Why?
| | Acute-Phase Proteins | 1 | 2019 | 67 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2022 | 383 | 0.040 |
Why?
| | Matched-Pair Analysis | 1 | 2019 | 40 | 0.040 |
Why?
| | Colorado | 2 | 2021 | 4405 | 0.040 |
Why?
| | Allografts | 1 | 2019 | 137 | 0.040 |
Why?
| | Testosterone | 1 | 2022 | 372 | 0.040 |
Why?
| | Monocytes | 1 | 2022 | 553 | 0.040 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.040 |
Why?
| | Half-Life | 1 | 2018 | 162 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2019 | 402 | 0.040 |
Why?
| | Hepatocytes | 1 | 2019 | 215 | 0.040 |
Why?
| | Biological Availability | 1 | 2018 | 147 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 186 | 0.040 |
Why?
| | Complement C5a | 1 | 2018 | 70 | 0.040 |
Why?
| | Complement Membrane Attack Complex | 1 | 2018 | 37 | 0.040 |
Why?
| | Clone Cells | 1 | 2018 | 262 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2023 | 735 | 0.040 |
Why?
| | Chromosome Aberrations | 1 | 2018 | 140 | 0.040 |
Why?
| | Area Under Curve | 1 | 2018 | 306 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 287 | 0.040 |
Why?
| | Fathers | 1 | 2018 | 50 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2021 | 869 | 0.040 |
Why?
| | Ligands | 1 | 2019 | 621 | 0.030 |
Why?
| | Healthy Aging | 1 | 2018 | 34 | 0.030 |
Why?
| | TRPP Cation Channels | 1 | 2018 | 79 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2018 | 443 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 503 | 0.030 |
Why?
| | Organ Size | 1 | 2017 | 456 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2018 | 5759 | 0.030 |
Why?
| | Congenital Abnormalities | 1 | 2017 | 76 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2021 | 858 | 0.030 |
Why?
| | Adolescent | 3 | 2021 | 20415 | 0.030 |
Why?
| | Body Mass Index | 2 | 2017 | 2274 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 787 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2018 | 520 | 0.030 |
Why?
| | Up-Regulation | 1 | 2019 | 836 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1087 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1270 | 0.030 |
Why?
| | Graft Rejection | 1 | 2019 | 598 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2018 | 3394 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 2018 | 228 | 0.030 |
Why?
| | Waiting Lists | 1 | 2017 | 238 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2019 | 724 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 851 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2024 | 1220 | 0.030 |
Why?
| | Neuroimaging | 1 | 2018 | 279 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2019 | 851 | 0.030 |
Why?
| | Pregnancy | 2 | 2018 | 6412 | 0.030 |
Why?
| | Autoimmunity | 1 | 2019 | 863 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1950 | 0.030 |
Why?
| | Protein Binding | 1 | 2019 | 2122 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2018 | 593 | 0.030 |
Why?
| | Survival Rate | 1 | 2018 | 1872 | 0.030 |
Why?
| | Recovery of Function | 1 | 2017 | 642 | 0.030 |
Why?
| | Glucose | 1 | 2018 | 1003 | 0.030 |
Why?
| | Premature Birth | 1 | 2017 | 317 | 0.030 |
Why?
| | Overweight | 1 | 2017 | 531 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2019 | 1368 | 0.030 |
Why?
| | Genotype | 1 | 2018 | 1829 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2019 | 2888 | 0.030 |
Why?
| | Age Factors | 1 | 2020 | 3153 | 0.020 |
Why?
| | Autoantibodies | 1 | 2019 | 1468 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 731 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2020 | 14525 | 0.020 |
Why?
| | Proteomics | 1 | 2018 | 1058 | 0.020 |
Why?
| | Cytokines | 1 | 2019 | 2022 | 0.020 |
Why?
| | Hyperlipidemias | 1 | 2011 | 126 | 0.020 |
Why?
| | Income | 1 | 2011 | 188 | 0.020 |
Why?
| | Rats | 1 | 2018 | 5485 | 0.020 |
Why?
| | Mental Recall | 1 | 2011 | 191 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4076 | 0.020 |
Why?
| | Social Class | 1 | 2011 | 259 | 0.020 |
Why?
| | Blood Glucose | 1 | 2018 | 2102 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2011 | 401 | 0.020 |
Why?
| | Educational Status | 1 | 2011 | 473 | 0.020 |
Why?
| | Learning | 1 | 2011 | 403 | 0.020 |
Why?
| | Infant | 1 | 2018 | 8987 | 0.010 |
Why?
| | Smoking | 1 | 2011 | 1502 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2011 | 1003 | 0.010 |
Why?
| | Depression | 1 | 2011 | 1322 | 0.010 |
Why?
|
|
You's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|